Cohen Investment Advisors LLC Grows Stake in AstraZeneca PLC (NASDAQ:AZN)

Cohen Investment Advisors LLC grew its stake in AstraZeneca PLC (NASDAQ:AZN) by 3.7% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 7,230 shares of the company’s stock after purchasing an additional 261 shares during the period. Cohen Investment Advisors LLC’s holdings in AstraZeneca were worth $474,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of AZN. Martin Investment Management LLC boosted its position in shares of AstraZeneca by 2.8% in the 3rd quarter. Martin Investment Management LLC now owns 284,204 shares of the company’s stock valued at $22,571,000 after purchasing an additional 7,615 shares during the period. Nordea Investment Management AB acquired a new stake in shares of AstraZeneca in the fourth quarter valued at approximately $754,000. Integrated Advisors Network LLC grew its position in shares of AstraZeneca by 46.6% during the third quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company’s stock worth $3,398,000 after acquiring an additional 13,860 shares during the last quarter. Creative Planning increased its holdings in shares of AstraZeneca by 8.0% in the 3rd quarter. Creative Planning now owns 224,751 shares of the company’s stock valued at $17,510,000 after acquiring an additional 16,692 shares during the period. Finally, Soros Fund Management LLC increased its stake in AstraZeneca by 8.2% in the third quarter. Soros Fund Management LLC now owns 2,652,771 shares of the company’s stock valued at $206,677,000 after purchasing an additional 201,233 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Trading Up 1.9 %

NASDAQ:AZN opened at $66.91 on Friday. The company has a market capitalization of $207.46 billion, a PE ratio of 32.01, a price-to-earnings-growth ratio of 1.05 and a beta of 0.46. AstraZeneca PLC has a 52-week low of $60.47 and a 52-week high of $87.68. The stock has a fifty day simple moving average of $66.02 and a 200-day simple moving average of $74.62. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71.

AstraZeneca (NASDAQ:AZN) last posted its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The firm had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. During the same quarter in the prior year, the company earned $0.87 EPS. AstraZeneca’s revenue was up 18.0% on a year-over-year basis. On average, equities research analysts expect that AstraZeneca PLC will post 4.11 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. UBS Group upgraded shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Two analysts have rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.